sifrol pramipexole dihydrochloride tablet 0

Description

Indication & Scope

Sifrol® is a prescription non-ergoline dopamine agonist indicated for the treatment of adult patients with idiopathic Parkinson’s disease throughout the disease course. It can be used as monotherapy without levodopa or in combination with levodopa, particularly in patients with end-of-dose deterioration or “on-off” motor fluctuations during advanced disease.It is also indicated for the symptomatic treatment of moderate-to-severe idiopathic restless legs syndrome (RLS) in adults.

Mechanism: Pramipexole is a selective dopamine D2/D3 receptor agonist that stimulates central dopaminergic pathways to improve motor symptoms and sensory symptoms associated with Parkinson’s disease and RLS.
Drug class: Non-ergoline dopamine D2/D3 receptor agonist.
Clinical use: Parkinson’s disease treatment and symptomatic management of restless legs syndrome.

Specification

Generic Name	Pramipexole Dihydrochloride Tablets
Brand Name	Sifrol®
Ingredient	Pramipexole Dihydrochloride
Dosage Form	Tablet
Package	0.25 mg/tablet, 30 tablets/carton
Conditions Treated	Parkinson’s disease; Restless Legs Syndrome
Taboos	Hypersensitivity to pramipexole or any component of the product
Place of origin	Germany
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 30°C, protected from light and moisture.
Manufacturer	Boehringer Ingelheim Pharma GmbH & Co. KG
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	HJ20140917
Approval Date	August 15, 2024
Shelf Life	36 months

How to use ?

Recommended Dose: For Parkinson’s disease, the initial dose is 0.125 mg three times daily, gradually increased according to response and tolerability. The maximum recommended daily dose is 4.5 mg. For restless legs syndrome, the usual starting dose is 0.125 mg once daily before bedtime.

Time: Take orally at regular intervals. It may be taken with or without food.

Instructions for use: Swallow tablets with water. Do not discontinue treatment abruptly; dose reduction should be gradual under medical supervision.

Interaction: Pramipexole may interact with levodopa, antipsychotics, sedatives, alcohol, antihypertensive agents, and renal cationic transport inhibitors.

Side effects: Common adverse reactions include nausea, dizziness, somnolence, insomnia, constipation, hallucinations, orthostatic hypotension, fatigue, and peripheral edema.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support